all report title image

GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Antihistamine Drugs Market, By Drug Class (H-1 Antihistamines (First-generation, Second-generation) and H-2 Antihistamines), By Form (Liquid, Tablets, Capsules, Gels, Nasal Sprays, and Others), By Indication (Allergic Disorders, Gastrointestinal Disorders, Central Nervous System Disorders, Dermatological Disorders, and Others), By Route of Administration (Oral, Parenteral, and Others), By Type (OTC and Prescription), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

  • Published In : Feb 2024
  • Code : CMI6700
  • Pages :155
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

The antihistamine drugs market is estimated to be valued at USD 94.72 Bn in 2024 and is expected to reach USD 154.24 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

Antihistamine drugs are a class of medications that are used to treat symptoms of allergies, such as sneezing, itching, runny nose, and watery eyes. These drugs work by blocking the action of histamine, a substance in the body that is released during an allergic reaction. There are two main types of antihistamines: First-generation antihistamines and second-generation antihistamine. Antihistamines are available over-the-counter and by prescription, depending on the specific medication and its strength. They come in various forms, including tablets, capsules, liquids, nasal sprays, and eye drops.

Market Dynamics:

The antihistamine drugs market is expected to witness significant growth over the forecast period owing to rise in the prevalence of allergies coupled, new product launches and approvals of innovative formulations. For instance, in June 2021, the U.S. Food and Drug Administration approved a nasal antihistamine for nonprescription use through a process known as a partial prescription to nonprescription switch. The U.S. FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis (also known as allergies) in adults and children aged six and older.

Key Features of the Study:

  • This report provides an in-depth analysis of the global antihistamine drugs market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global antihistamine drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Bayer AG, Almirall, S.A, GlaxoSmithKline, Johnson and Johnson, Sanofi, Pfizer Inc., Sun Pharmaceutical Industries Limited, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Viatris Inc., Arlak Biotech, Aden Healthcare, Sandoz Group AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, and Cipla
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global antihistamine drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antihistamine drugs market

Detailed Segmentation:

  • By Drug Class:
    • H-1 Antihistamines
      • First-generation
      • Second-generation
    • H-2 Antihistamines
  • By Form:
    • Liquid
    • Tablets
    • Capsules
    • Gels
    • Nasal Sprays
    • Others
  • By Indication:
    • Allergic Disorders
    • Gastrointestinal Disorders
    • Central Nervous System Disorders
    • Dermatological Disorders
    • Others
  • By Route of Administration:
    • Oral
    • Parenteral
    • Others
  • By Type:
    • OTC
    • Prescription
  • By Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • By Region: 
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Bayer AG
    • Almirall S.A
    • GlaxoSmithKline
    • Johnson and Johnson
    • Sanofi
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Limited
    • Merck & Co. Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Abbott Laboratories
    • Viatris Inc.
    • Arlak Biotech
    • Aden Healthcare
    • Sandoz Group AG
    • Hikma Pharmaceuticals PLC
    • Reddy's Laboratories
    • Cipla

Detailed Segmentation:

  • By Drug Class:
    • H-1 Antihistamines
      • First-generation
      • Second-generation
    • H-2 Antihistamines
  • By Form:
    • Liquid
    • Tablets
    • Capsules
    • Gels
    • Nasal Sprays
    • Others
  • By Indication:
    • Allergic Disorders
    • Gastrointestinal Disorders
    • Central Nervous System Disorders
    • Dermatological Disorders
    • Others
  • By Route of Administration:
    • Oral
    • Parenteral
    • Others
  • By Type:
    • OTC
    • Prescription
  • By Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • By Region: 
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.